10-Q: enVVeno Medical Reports Widening Losses Amid Promising VenoValve Clinical Data and Rising Cash Burn

enVVeno Medical Corporation reported increased net losses for the second quarter of 2025, driven by higher operating expenses, while advancing its VenoValve and enVVe medical device programs with positive clinical and preclinical results.

Summary

• Net loss increased by 35% to $6.7 million for the three months ended June 30, 2025, compared to $5.0 million for the same period in 2024.
• For the six months ended June 30, 2025, net loss increased by 13% to $11.2 million, from $9.9 million for the same period in 2024.
• Selling, general and administrative expenses rose significantly by 58% to $4.2 million for the three months ended June 30, 2025, primarily due to higher compensation costs, a non-recurring $0.3 million severance expense, and a non-recurring $0.6 million reserve for potentially uncollectible prepaid clinical costs.
• Cash and investments decreased by $8.1 million from $43.2 million at December 31, 2024, to $35.1 million at June 30, 2025.
• Net cash used in operating activities increased to $7.7 million for the six months ended June 30, 2025, from $7.5 million for the same period in 2024.
• The VenoValve U.S. pivotal study's interim two-year follow-up data showed 83.3% of patients maintained a clinically meaningful benefit, with an average rVCSS improvement of 9.1 points and 60% of venous ulcers healing completely.
• The final wave of implants for the six-month pre-clinical GLP study for enVVe was successfully completed in December 2024, with an IDE filing for the enVVe pivotal study expected in Q3 2025.
• The final module of the PMA application for VenoValve was submitted to the FDA on November 19, 2024, with an FDA decision expected in the second half of 2025.

Sentiment

Score: 6

Explanation: The company shows strong clinical progress with its lead product, VenoValve, and advances with enVVe, addressing a significant unmet medical need. However, increasing net losses, rising operating expenses, and a higher cash burn rate, coupled with the explicit need for future capital raises and a non-recurring charge for uncollectible clinical costs, temper the overall financial outlook.

Positives

• VenoValve's two-year interim data from the U.S. pivotal trial demonstrated sustained clinical benefit, with 83.3% of patients (n=35/42) maintaining a clinically meaningful improvement in revised Venous Clinical Severity Score (rVCSS).
• The average rVCSS improvement in the clinically meaningful responder cohort was 9.1 points at two years.
• Patients in the VenoValve study experienced a 74% median reduction in leg pain, as measured by the Visual Analog Scale (VAS), at two years.
• For patients with venous ulcers (CEAP C6 patients), wound healing outcomes showed that 60% of ulcers healed completely (n=17 patients with 25 ulcers).
• A 100% valve patency rate was observed at the two-year follow-up for a subset of 30 patients.
• Successful completion of the final wave of implants for the six-month pre-clinical GLP study for enVVe, a prerequisite for seeking IDE approval.
• VenoValve has been granted Breakthrough Device designation by the FDA, which may shorten the PMA review process.

Negatives

• Net loss increased by 35% to $6.7 million for the three months ended June 30, 2025, compared to $5.0 million for the same period in 2024.
• Selling, general and administrative expenses increased significantly by 58% to $4.2 million for the three months ended June 30, 2025.
• A non-recurring $0.3 million severance expense was recorded in Q2 2025, contributing to increased SG&A expenses.
• A non-recurring $0.6 million reserve for potentially uncollectible prepaid clinical costs was recorded in Q2 2025, due to payments made to a vendor not passed through to clinical sites.
• Cash and investments decreased by $8.1 million from $43.2 million at December 31, 2024, to $35.1 million at June 30, 2025.
• Net cash used in operating activities increased to $7.7 million for the six months ended June 30, 2025, from $7.5 million for the same period in 2024.

Risks

• The company expects to continue incurring losses for the foreseeable future.
• Future capital requirements are dependent on the success of clinical trials, related product development costs, and the ability to successfully bring products to market.
• The cash burn rate is anticipated to increase from current levels of approximately $4 million per quarter to between $5 million and $7 million per quarter.
• There is no assurance that either the VenoValve or enVVe will receive approval from the U.S. Food and Drug Administration (FDA).
• A non-recurring $0.6 million reserve for potentially uncollectible prepaid clinical costs highlights a risk related to vendor management and financial controls.
• The PMA process for VenoValve has an unpredictable timeline, despite its Breakthrough Device designation, with an estimated FDA decision in the second half of 2025.

Future Outlook

The company expects to continue incurring losses for the foreseeable future and anticipates its cash burn rate will increase from approximately $4 million per quarter to between $5 million and $7 million per quarter. Management believes current capital resources are sufficient for at least one year, but the company may need to raise additional capital to sustain operations, pursue product development, and penetrate markets. An FDA decision for the VenoValve is expected during the second half of 2025, and the company expects to file for IDE approval for the enVVe pivotal study in the third quarter of 2025, with enVVe FDA approval anticipated two to three years after VenoValve.

Management Comments

• Management believes the company's capital resources of $35.1 million cash and investments and $32.6 million working capital as of June 30, 2025, are sufficient to meet obligations for at least one year and sustain operations.
• The company anticipates its cash burn rate will increase from current levels of approximately $4 million per quarter to between $5 million and $7 million per quarter as clinical studies are conducted and product candidates are brought to market.
• The company expects to file for IDE approval for the enVVe pivotal study in the third quarter of 2025.
• The company's best estimate is to expect an FDA decision on the VenoValve PMA application during the second half of 2025.

Industry Context

enVVeno Medical operates in the medical device sector, specifically targeting deep venous disease, a highly prevalent chronic condition with significant unmet medical needs. The company is developing potential first-of-its-kind surgical (VenoValve) and non-surgical (enVVe) replacement venous valves. Currently, there are no FDA-approved devices for surgical or non-surgical replacement venous valves, nor are there effective treatments for deep venous Chronic Venous Insufficiency (CVI) caused by incompetent valves. This positions enVVeno Medical as a potential innovator in a market with a large patient population (estimated 20 million in the U.S. with severe deep venous CVI) and high associated healthcare costs (exceeding $3 billion annually for venous ulcer sufferers).

Comparison to Industry Standards

• There are currently no devices FDA approved as surgical or non-surgical replacement venous valves, and there are currently no effective treatments for deep venous CVI caused by incompetent valves, positioning enVVeno Medical as a potential first-to-market innovator if VenoValve receives approval.
• The VenoValve's two-year interim clinical data, showing 83.3% of patients maintaining a clinically meaningful benefit and 60% ulcer healing, suggests a significant improvement over the current lack of effective treatments for severe deep venous CVI.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders face potential dilution from future capital raises but could see significant value appreciation if VenoValve receives FDA approval and is successfully commercialized.
• Employees are impacted by compensation costs, including stock-based compensation, and potential severance, as seen with the non-recurring severance expense.
• Patients suffering from severe Chronic Venous Insufficiency (CVI) could benefit significantly from the VenoValve and enVVe if they receive FDA approval, as there are currently no effective treatments for deep venous CVI caused by incompetent valves.
• Creditors and investors should note the increasing cash burn and the explicit statement regarding the need for additional capital, which impacts the company's financial stability and ability to meet future obligations.

Next Steps

• FDA decision on the VenoValve PMA application expected during the second half of 2025.
• Expected filing for IDE approval for the enVVe pivotal study in the third quarter of 2025.
• Continued clinical studies and product development for VenoValve and enVVe.
• Preparation for commercialization of the VenoValve, if approved.

Key Dates

Recommendation

While enVVeno Medical presents compelling clinical data for its VenoValve, addressing a critical unmet medical need, the company remains in a pre-revenue, developmental stage. The increasing net losses and cash burn rate, alongside the explicit need for future capital raises, introduce significant financial risk. The non-recurring charge for uncollectible clinical costs also highlights operational vulnerabilities. Investors should hold, monitoring FDA approval progress for VenoValve and the company's ability to secure additional financing without excessive dilution, as these factors will be critical determinants of future value.

Keywords

Medical device, Deep venous disease, Chronic Venous Insufficiency, CVI, VenoValve, enVVe, FDA approval, Clinical trial, Pre-clinical testing, Quarterly Report, Financial results, Bioprosthetic solutions